APA (7th ed.) Citation

B, G., CM, Z., LV, M., J, M., F, B., M, C., . . . T, T. (2020). Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): A multicentre phase 1-2 study. The Lancet. Oncology, 21(1), 134. https://doi.org/10.1016/S1470-2045(19)30693-X

Chicago Style (17th ed.) Citation

B, Geoerger, et al. "Atezolizumab for Children and Young Adults with Previously Treated Solid Tumours, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma (iMATRIX): A Multicentre Phase 1-2 Study." The Lancet. Oncology 21, no. 1 (2020): 134. https://doi.org/10.1016/S1470-2045(19)30693-X.

MLA (9th ed.) Citation

B, Geoerger, et al. "Atezolizumab for Children and Young Adults with Previously Treated Solid Tumours, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma (iMATRIX): A Multicentre Phase 1-2 Study." The Lancet. Oncology, vol. 21, no. 1, 2020, p. 134, https://doi.org/10.1016/S1470-2045(19)30693-X.